Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States
Pain Medicine · 2026
DOI: 10.1093/pm/pnag055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Medicine, 2026. Verfasst von Nathaniel M Schuster und 6 weiteren Autor:innen. Beteiligte Einrichtung: UC San Diego Health, San Diego, CA, United States. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Analgesics, Neuralgia, Practice Patterns, Physicians'. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.
Abstract (Originalsprache)
Objective
This study analyzes real-world treatment patterns among patients newly initiating treatment for painful diabetic peripheral neuropathy using a contemporary dataset in the United States.
Methods
A retrospective study using the MarketScan database (January 1, 2016, to June 30, 2023) identified adults newly prescribed pain medication(s) used to treat neuropathic pain within 60 days of a diabetic peripheral neuropathy diagnosis. Patients with prior medication, conditions with similar treatment indications, cancer, or major surgery were excluded. Treatment patterns over a 12-month period and variable-length follow-up (four sequential treatment episodes) were captured, including treatment type, dosage, adherence, discontinuation (≥90-day gap), and switching.
Results
Among 22 955 patients identified, 98.5% initiated monotherapy treatment for painful diabetic peripheral neuropathy. The majority initiated treatment with gabapentinoids (gabapentin 59.0%; pregabalin 5.3%), followed by opioids (tramadol 15.1%, oxycodone 7.0%), and antidepressants (duloxetine 5.2%). Among patients initiating gabapentin, pregabalin, or duloxetine, most were prescribed daily doses below recommended levels (79% gabapentin, 91% pregabalin, 61% duloxetine), and the majority (81%–96%) did not increase their dose. Adherence was low. Over 50% discontinued their initial treatment within 3 months, and approximately 75% discontinued in the 12-month follow-up period, with fewer than 25% switching to another medication. When evaluating treatment patterns across sequential treatment episodes, almost 65% discontinued all pain medications and did not receive subsequent treatment by the fourth treatment episode.
Conclusions
High rates of treatment discontinuation and suboptimal adherence likely indicate challenges with tolerability and insufficient pain relief associated with current therapies for painful diabetic neuropathy. These findings emphasize the limitations of existing treatment options and highlight the unmet need for more effective and better-tolerated treatments for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UC San Diego Health, San Diego, CA, United States.
- Vertex Pharmaceuticals Incorporated, Boston, MA, United States.
- MarketScan by Merative, Ann Arbor, MI, United States.
- Albany Medical College, Albany, NY, United States.
ORCID-Profile: Ann M Menzie
Förderung
- Vertex Pharmaceuticals Incorporated
Zitieren
APA
Schuster, N. M., Jeyakumar, S., Menzie, A. M., Panni, M., Princic, N., Moynihan, M., & Argoff, C. E. (2026). Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States. Pain Medicine. https://doi.org/10.1093/pm/pnag055
Vancouver
Schuster NM, Jeyakumar S, Menzie AM, Panni M, Princic N, Moynihan M, et al. Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States. Pain Medicine. 2026. doi:10.1093/pm/pnag055
BibTeX
@article{Schuster2026,
author = {Schuster, Nathaniel M and Jeyakumar, Sushanth and Menzie, Ann M and Panni, Moeen and Princic, Nicole and Moynihan, Meghan and Argoff, Charles E},
title = {Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States},
journal = {Pain Medicine},
year = {2026},
doi = {10.1093/pm/pnag055}
}
EUVIMED